<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="hold an issued patent on the treatment of parenteral nutrition-associated" exact="liver disease." post="The patent numbers are 9,566,260 and 9,629,821 under the"/>
 <result pre="9,566,260 and 9,629,821 under the name &quot;Treatment and prevention of" exact="liver disease" post="associated with parenteral nutrition (PN).&quot; This does not alter"/>
 <result pre="original author and source are credited. pone.0217155.pdf Abstract Intestinal failure-associated" exact="liver disease" post="(IFALD) is a risk of parenteral nutrition (PN)-dependence. Intravenous"/>
 <result pre="administration. One such complication is the development of intestinal failure-associated" exact="liver disease" post="(IFALD), which is characterized by cholestatic liver disease that"/>
 <result pre="intestinal failure-associated liver disease (IFALD), which is characterized by cholestatic" exact="liver disease" post="that can progress to cirrhosis and end-stage liver disease"/>
 <result pre="is characterized by cholestatic liver disease that can progress to" exact="cirrhosis" post="and end-stage liver disease necessitating liver transplantation. Traditionally, the"/>
 <result pre="cholestatic liver disease that can progress to cirrhosis and end-stage" exact="liver disease" post="necessitating liver transplantation. Traditionally, the progression of IFALD could"/>
 <result pre="liver injury in animal models [ 1, 2] and reverse" exact="cholestasis" post="and stop or slow the progression of liver disease"/>
 <result pre="and reverse cholestasis and stop or slow the progression of" exact="liver disease" post="in patients with IFALD [ 3– 9]. Fat is"/>
 <result pre="fat source to patients who develop IFALD, FO can reverse" exact="cholestasis" post="and stop the progression of liver disease (3–9). While"/>
 <result pre="IFALD, FO can reverse cholestasis and stop the progression of" exact="liver disease" post="(3–9). While the mechanisms for the hepatoprotective properties of"/>
 <result pre="et al, that did not find improvement in markers of" exact="cholestasis" post="with the addition of α-tocopherol to a commercially available"/>
 <result pre="and accumulation of hepatic triglycerides in murine models of nonalcoholic" exact="fatty liver disease" post="[ 31– 33]. The hepatic triglyceride-accumulating STAT5 knockout mice"/>
 <result pre="accumulation of hepatic triglycerides in murine models of nonalcoholic fatty" exact="liver disease" post="[ 31– 33]. The hepatic triglyceride-accumulating STAT5 knockout mice"/>
 <result pre="do have hepatotoxic properties and can affect the development of" exact="cholestasis" post="[ 17, 18]. This study demonstrates a role for"/>
 <result pre="hold an issued patent on the treatment of parenteral nutrition-associated" exact="liver disease." post="The patent numbers are 9,566,260 and 9,629,821 under the"/>
 <result pre="9,566,260 and 9,629,821 under the name &quot;Treatment and prevention of" exact="liver disease" post="associated with parenteral nutrition (PN).&quot; This does not alter"/>
 <result pre="supplementation prevents hepatic steatosis in a murine model of nonalcoholic" exact="fatty liver disease" post=". Pediatr Res. 2005; 57: 445– 452. 10.1203/01.PDR.0000153672.43030.75 15659701"/>
 <result pre="prevents hepatic steatosis in a murine model of nonalcoholic fatty" exact="liver disease" post=". Pediatr Res. 2005; 57: 445– 452. 10.1203/01.PDR.0000153672.43030.75 15659701"/>
 <result pre="paradigm: omegaven for the treatment of liver failure in pediatric" exact="short bowel syndrome" post=". J Pediatr Gastroenterol Nutr. 2009; 48: 209– 15."/>
 <result pre=", Bistrian BR , et al. Reversal of parenteral nutrition-associated" exact="liver disease" post="in two infants with short bowel syndrome using parenteral"/>
 <result pre="Reversal of parenteral nutrition-associated liver disease in two infants with" exact="short bowel syndrome" post="using parenteral fish oil: implications for future management ."/>
 <result pre=", Fischler B . Impact of parenteral fat composition on" exact="cholestasis" post="in preterm infants. J Pediatr Gastroenterol Nutr. 2015; 60:"/>
 <result pre="promote liver injury and Kupffer cell activation in parenteral nutrition-associated" exact="liver disease" post=". Sci Transl Med. 2013; 5: 206ra137 10.1126/scitranslmed.3006898 24107776"/>
</results>
